U.S. Roadside Drug Testing Devices Market

U.S. Roadside Drug Testing Devices Market Outlook 2031

• The roadside drug testing devices market in the U.S. was valued at US$ 298.9 Mn in 2021
• The market in the country is projected to expand at a CAGR of 5.3% from 2022 to 2031
• The roadside drug testing devices market in the U.S. is anticipated to reach US$ 498.8 Mn by the end of 2031

Analysts’ Viewpoint on U.S. Roadside Drug Testing Devices Market Scenario

The roadside drug testing devices market in the U.S. has been witnessing strong growth over the last few years due to the increase in consumption of various illicit drugs and alcohol in the country. Currently, cannabis is used in medicines to treat various conditions. This has led to legalization of the drug, which in turn has increased the drug consumption rate. Drug-impaired driving is responsible for a large number of accidents. It has resulted in an increase in demand for roadside drug testing in order to prevent accidents. Manufacturers should focus on developing advanced drug testing devices such as mobile alcohol breathalyzers to increase revenue opportunities.

Overview of U.S. Roadside Drug Testing Devices Market

Roadside drug testing devices are used to identify drugs consumed by an individual while driving. Devices used for drug testing include breathalyzers and drug test kits. It has become mandatory to conduct drug driving testing to prevent accidents and mishaps. In 2020, around 11,654 people died due to alcohol-impaired driving in the U.S., a 14% increase over that in 2019. Increase in the number of drug and alcohol abusers in the U.S. presents significant opportunities for test providers and manufacturers of drug abuse test products in the market.

Impact of Drug Abuse on Public Health to Drive Demand for Testing

Substance abuse has a significant effect on the health of individuals and their families. Abuse of prescription drugs or nonmedical use of prescription drugs has become a grave public health concern owing to its high prevalence and mortality rate in the U.S. Several individuals consume such drugs and drive, which leads to major accidents. Hence, roadside drug screening devices are used regularly to test individuals. This, in turn, propels the market in the country.

Rise in prescription drug abuse increases the rate of overdose deaths and emergency room visits. Consumption of non-medical prescription drugs is rising at a rapid pace. According to the National Institute of Drug Abuse (NIDA), around 52 million people have used prescription drugs for non-medical reasons at least once in their lifetime. Vicodin and OxyContin are the most abused prescription drugs among the young population.

Technological Advancements in Testing Devices to Boost U.S. Roadside Drug Testing Devices Market

Technological advancements related to sample collection and efforts of manufacturers to create easy-to-use disposable test kits are expected to boost the demand for roadside drug testing devices. Manufacturers are focusing on using samples other than urine, such as sweat and hair, which are less embarrassing for individuals tested for drug abuse. They are also focusing on the development of rapid tests that provide faster results; and are easy to use and more affordable than wet tests. For instance, the DDS2 Mobile Test System, designed and manufactured by Alere, Inc. (Abbott), is a next-generation portable drug testing device. It detects if a driver is addicted to cocaine, marijuana, opiates, amphetamines, and methamphetamines in a single oral fluid test within five minutes.

Increase in Demand for Alcohol Testing Devices to Augment U.S. Roadside Drug Testing Devices Market

Based on substance, the roadside drug testing devices market in the U.S. has been bifurcated into drugs and alcohol. The drugs segment has been split into tetrahydrocannabinol (THC), cocaine, amphetamine, and others. The alcohol segment dominated the market in the U.S. in 2021, accounting for around 62% share. The segment is likely to grow at a rapid pace during the forecast period. According to CDC, around 10,511 alcohol-impaired driving deaths occurred in the U.S. in 2018. Implementation of strategies to prevent alcohol and drug-impaired driving in the country is propelling the alcohol segment.

Higher Accuracy and Ease of Collection & Storage to Boost Urine Sample Segment

Based on sample, the roadside drug testing devices market in the U.S. has been segregated into saliva, breath, urine, and others. The urine segment held major share of around 42% in 2021. The trend is projected to continue during the forecast period. Urine samples are easy to store. Urine tests also give accurate results. These are non-invasive procedures used by professionals to detect illegal consumption of drugs. The breath segment held the second largest share of the market in the country in 2021. The segment is driven by the increase in the number of cases of driving under the influence of alcohol.

High Portability and Low Cost to Drive Sales of Handheld Modality Devices

In terms of modality, the roadside drug testing devices market in the U.S. has been segregated into handheld and standalone. The handheld segment dominated the roadside drug testing devices market in the country in 2021, accounting for 73% share. The segment is anticipated to grow at the fastest CAGR during the forecast period. This can be attributed to high portability and low cost associated with handheld devices. Increase in sales of these compact roadside drug testing devices can be ascribed to their small size, speed, and reliability.

Analysis of Key Market Players in U.S. Roadside Drug Testing Devices Market

The roadside drug testing devices market report concludes with the company profiles section, which includes key information about leading players in the roadside drug testing devices market in the U.S. Most of the key players play an active role in the introduction of new mobile devices as well as point-of-care testing devices. Leading players in the roadside drug testing devices market in the country include Abbott, Quest Products, LLC, CareHealth America Corporation, Oranoxis, Inc., Drägerwerk AG & Co. KGaA, BACtrack, and Lifeloc Technologies, Inc.

Key Developments in U.S. Roadside Drug Testing Devices Market

• In 2019, Abbott’s SoToxa was approved by the Federal Government. SoToxa is a mobile test system that has been designed for rapid drug screening as well as detection of drugs in oral fluid.
• On January 30, 2020, Lifeloc Technologies, Inc. achieved Reference Material Producer Accreditation for Alcohol Simulator Solution by the American Association for Laboratory Accreditation
• In May 2020, Psychemedics Corporation announced the introduction of a new test (vaping panel test). This test detects the presence of cannabidiol (CBD) and nicotine drugs in a sample.

Each of these players has been profiled in the roadside drug testing devices market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. The report also focuses on demand analysis of roadside drug testing devices.

U.S. Roadside Drug Testing Devices Market Snapshot